|
|
| | ACTB-1003 Basic information |
| Product Name: | ACTB-1003 | | Synonyms: | ACTB-1003;N-[4-[4-Amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl]urea;Urea, N-[4-[4-amino-6-(methoxymethyl)-7-(4-morpholinylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-N'-[2-fluoro-5-(trifluoromethyl)phenyl];ACTB1003;ACTB 1003;1-[4-[4-amino-6-(methoxymethyl)-7-(morpholin-4-ylmethyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-2-fluorophenyl]-3-[2-fluoro-5-(trifluoromethyl)phenyl]urea;FGFR,Fibroblast growth factor receptor,Vascular endothelial growth factor receptor,inhibit,EOC317,Inhibitor,VEGFR,EOC-317,EOC 317;EOC317, 10 mM in DMSO;EDP-317 | | CAS: | 939805-30-8 | | MF: | C27H26F5N7O3 | | MW: | 591.53 | | EINECS: | | | Product Categories: | | | Mol File: | 939805-30-8.mol |  |
| | ACTB-1003 Chemical Properties |
| density | 1.51±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.33 mg/ml; Ethanol: 1 mg/ml | | pka | 12.47±0.70(Predicted) | | form | Powder | | color | White to off-white |
| | ACTB-1003 Usage And Synthesis |
| Uses | ACTB-1003 is an oral kinase inhibitor which is used in the targeting of cancers. | | in vivo | EOC317 (ACTB-1003) is shown to inhibit tumor angiogenesis evident by the inhibition of CD31 staining in tumor sections. EOC317 is combinable with 5-FU or paclitaxel without diminishing the activity or increasing the toxicity of these chemotherapy agents in the HCT-116 colon tumor xenograft model[1]. | | IC 50 | FGFR1: 6 nM (IC50); VEGFR2: 2 nM (IC50); Tie-2: 4 nM (IC50) |
| | ACTB-1003 Preparation Products And Raw materials |
|